Clover Biopharmaceuticals is a clinical-stage biotechnology company focused on developing vaccines and biologic therapeutic.
Clover Biopharmaceuticals is a global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune diseases. Clover is utilizing its proprietary Trimer-Tag© technology platform to develop novel biologics targeting trimerization-dependent pathways. Additionally, Clover is leveraging its in-house cGMP biomanufacturing capabilities to develop select biosimilars.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 27, 2019 | Series B | ¥304M | 4 | — | — | Detail |
Dec 14, 2017 | Series A | ¥62.80M | 1 | Tianhe Life Sciences Venture Fund | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Tianhe Life Sciences Venture Fund | Yes | Series A |
Sichuan Province Healthy Pension Industry Equity Investment Fund | — | Series B |
Jinlong Group | — | Series B |
Zhongguancun VC Development Center | — | Series B |
Beida Biomedical Industry Fund | — | Series B |